Press Releases

For Media or Press inquiries
Contact
Tel: 212-660-7250
Fax:
Email: eric.zitter@achelous.com

June 2, 2017
Achelous Partners Advises Coté Orphan, LLC on its sale to QuintilesIMS

May 3, 2017
Achelous Partners Advises PharmaCell B.V. on its sale to Lonza Group Ltd.

April 25, 2017
Achelous Partners Advises Emergo Group, Inc. on its sale to UL LLC

April 21, 2017
Achelous Partners Advises Calbiotech, Inc. on its sale to Transasia Bio-Medicals / Erba Mannheim

January 4, 2017
Achelous Partners Advises BioControl Systems Inc. on its sale to Merck KGaA / MilliporeSigma (XETRA: MRK)

August 31, 2016
Achelous Partners Advises SPEware Corporation on its sale to Tecan Group (SIX: TECN)

July 6, 2016
Achelous Partners Advises Sharps Compliance Corp. (Nasdaq: SMED) on its acquisition of Citiwaste, LLC

June 20, 2016
Dr. Jan Boesen discusses M&A strategy and how to best maximize value in a trade sale at BIO-Europe in Stockholm

June 16, 2016
Achelous Partners Advises Argos Soditic and CisBio Bioassays on its sale to Abénex

December 15, 2015
Achelous Partners Advises Sharps Compliance Corp. (Nasdaq: SMED) on its acquisition of Bio-Team Mobile

November 24, 2015
Achelous Partners Advises Abzena plc (AIM: ABZA) on its acquisition of The Chemistry Research Solution LLC (“TCRS”)

September 22, 2015
Achelous Partners Advises Kinesis Pharma BV on its sale to Venn Life Sciences Holding Plc (AIM: VENN)

August 26, 2015
Achelous Partners Advises DIAsource ImmunoAssays on its sale to Anteo Diagnostics (ASX: ADO)

July 20, 2015
Achelous Partners Advises Sharps Compliance Corp. on its acquisition of Alpha Bio/Med Services

May 19, 2015
Dr. Jan Boesen joins Achelous Partners, LLC as its European Representative

March 31, 2015
Achelous Partners Advises Ansell Limited on its acquisition of Microgard Ltd.

August 18, 2014
Achelous Partners advises Valeant Pharmaceuticals (NYSE: VRX) on its acquisition of ophthalmology and orthopedic assets from Croma Pharma GmbH

July 30, 2014
Achelous Partners Advises IBL International Holding BV on its sale to Tecan Group (SIX: TECN)

July 14, 2014
Achelous Partners CoAdvises Phlexglobal Limited on its sale to Bridgepoint Development Capital

June 18, 2014
Achelous Partners Advises Spectris plc (LSE: SXS) on its acquisition of La Corporation Scientifique Claisse

April 23, 2014
Achelous Partners CoAdvises Pharmalink Consulting on its sale to Genpact (NYSE: G)

August 19, 2013
Achelous Partners Advises Kirkegaard & Perry Laboratories (KPL) on its sale to SeraCare Life Sciences

August 9, 2013
Achelous Partners Advises Austofix Group Limited on the sale of its orthopedic reconstruction business to Amplitude, an Apax Partners company

July 23, 2013
Achelous Partners Advises Matrical Bioscience Inc on its sale to Brooks Automation (NASDAQ: BRKS)

July 9, 2013
Achelous Partners Advises The Anson Group LLC on its sale to Navigant Consulting (NYSE: NCI)

July 8, 2013
Achelous Partners Advises Kreatech Diagnostics on its sale to Leica Biosystems/Danaher (NYSE: DHR)

May 22, 2013
Achelous Partners Advises Triangle Biomedical Sciences Inc on its sale to General Data

August 29, 2012
Achelous Partners Advises JSW Life Sciences GmbH on its sale to QPS LLC

March 13, 2012
Achelous Partners Advises Valeant Pharmaceuticals International Inc (NYSE: VRX) on its acquisition of assets from Gerot Lannach

December 23, 2011
Achelous Partners Advises Ansell Ltd (ASX: ANN) on its investment in Lakeland Industries Inc

August 30, 2010
Achelous Partners Advises EnviroLogix Inc on its sale to EnsignBickford Industries Inc

February 1, 2010
Achelous Partners Advises Finnzymes Oy on its sale to Thermo Fisher Scientific Inc (NYSE: TMO)

December 18, 2009
Achelous Partners Advises BTG plc (LSE: BGC) on the licensing of its ReGel® drug delivery system for ophthalmic indications to Allergan Inc

October 23, 2009
Achelous Partners Advises AnaSpec Inc on its sale to Eurogentec SA

August 28, 2009
Achelous Partners Advises BTG plc (LSE: BGC) on the sale of its HySolv™ drug delivery technology to Novartis Pharma AG for up to US$10 million

January 6, 2009
Achelous Partners Advises Labcoat Ltd on its sale to Boston Scientific Corp (NYSE: BSX)

December 8, 2008
Achelous Partners Advises Affymetrix Inc (NASDAQ: AFFX) on its acquisition of Panomics Inc for a total consideration of US$73 million

July 25, 2008
Achelous Partners Advises Biocompatibles (LSE: BII) on its acquisition of BrachySciences Inc and its affiliated companies for a total consideration of up to US$22 million

December 24, 2007
Achelous Partners Advises Sigma Pharmaceuticals Ltd (ASX: SIP) on its acquisition of Orphan Holdings Pty Ltd for a total consideration of A$130 million

October 8, 2007
Achelous Partners Advises Panbio Ltd (ASX: PBO) on its sale to Inverness Medical Innovations, Inc (AMEX: IMA) for a total consideration of A$41 million

May 4, 2007
Achelous Partners Advises Ansell Ltd (ASX: ANN) on its acquisition of Fabrica de Artefatos de Látex Blowtex Ltda of Brazil

December 21, 2006
Achelous Partners Advises GeneMedix plc (LSE: GMX) on its Proposed Restructuring involving a £32.1 million Proposed Strategic Investment by Reliance Life Sciences Pvt Ltd, part of the Reliance Group, India's Largest Private Sector Enterprise

December 21, 2006
Achelous Partners has been Appointed to Act as Financial Advisor to Panbio Limited (ASX: PBO), an International Medical Diagnostics Company

November 27, 2006
Achelous Partners Advises Novozymes (CPSE: NZYM B) on its acquisition of GroPep Ltd (ASX: GRO) for A$100 million

July 7, 2006
Achelous Partners Advises Novozymes (CPSE: NZYM B) on its acquisition of Delta Biotechnology Ltd from the sanofiaventis group

October 19, 2005
Achelous Partners has been Appointed to Act as Financial Advisor to CogState Ltd (ASX: CGS), a Melbourne based Clinical IT Company

October 6, 2005
Achelous Partners has been Appointed to Act as Financial Advisor to GeneMedix plc (LSE: GMX), a UK Biopharmaceutical Company, and its Restructuring Program

January 21, 2005
Achelous Partners Named Frost & Sullivan Pharmaceuticals BuySide M&A Advisor of the Year

October 20, 2004
Achelous Partners Advises Gribbles Group Ltd. (ASX: GGL) on its sale to Healthscope Ltd. Bid

  • June 2017
    has been acquired by
    The undersigned acted as financial advisor to Coté Orphan, LLC
  • May 2017
    has been acquired by
    The undersigned acted as financial advisor to PharmaCell B.V.
  • April 2017
    has been acquired by
    The undersigned acted as financial advisor to Emergo Group, Inc.
  • April 2017
    has been acquired by
    The undersigned acted as financial advisor to Calbiotech, Inc.
  • January 2017
    has been acquired by
    The undersigned acted as financial advisor to BioControl Systems, Inc.
  • August 2016
    has been acquired by
    The undersigned acted as financial advisor to SPEware Corporation
  • July 2016
    has acquired
    The undersigned acted as financial advisor to Sharps Compliance Corp.
  • June 2016
    has been acquired by
    The undersigned acted as financial advisor to Cisbio Bioassays
  • December 2015
    has acquired
    The undersigned acted as financial advisor to Abzena plc
  • December 2015
    has acquired
    The undersigned acted as financial adviser to Sharps Compliance Corp.
  • October 2015
    has been acquired by
    The undersigned acted as financial advisor to Kinesis Pharma BV
  • August 2015
    has been acquired by
    The undersigned acted as financial advisor to DIAsource ImmunoAssays SA
  • July 2015
    has acquired
    The undersigned acted as financial advisor to Sharps Compliance Corp.
  • March 2015
    has acquired
    The undersigned acted as financial advisor to Ansell Limited
  • July 2014
    has been acquired by
    The undersigned acted as financial advisor to IBL International Holding BV
  • July 2014
    has been acquired by
    The undersigned served as financial advisor to Phlexglobal Limited
  • June 2014
    has been acquired by
    The undersigned served as financial advisors to Pharmalink Consulting
  • December 2013
    has acquired assets from
    The undersigned acted as advisor to Valeant Pharmaceuticals International
  • August 2013
    has been acquired by
    The undersigned acted as financial advisor to Kirkegaard & Perry Laboratories Inc
  • July 2013
    has been acquired by
    The undersigned acted as financial advisor to The Anson Group LLC
  • July 2013
    has signed a definitive agreement to sell its orthopedic implant assets and business to
    an Apax Partners company The undersigned acted as financial advisor to Austofix Group Limited
  • July 2013
    has been acquired by
    The undersigned acted as financial advisor to Kreatech Holding B.V.
  • July 2013
    has been acquired by
    USD$10,000,000
    The undersigned acted as financial advisor to Matrical Bioscience Inc
  • May 2013
    has been acquired by
    The undersigned acted as advisor to Triangle Biomedical Sciences Inc.
  • August 2012
    has been acquired by
    The undersigned acted as advisor to JSW Life Sciences GmbH
  • March 2012
    has acquired assets from
    US$164M plus up to US$20M in milestones
    The undersigned acted as advisor to Valeant Pharmaceuticals International
  • December 2011
    invests in
    The undersigned acted as advisor to Ansell Limited for the investment
  • August 2010
    has been acquired by
    The undersigned acted as financial advisor to EnviroLogix, Inc.
  • March 2010
    has been acquired by
    USD$59,000,000
    The undersigned acted as financial advisor to Finnzymes Oy
  • December 2009
    has licensed its ReGet® drug delivery system for ophthalmic indications to
    The undersigned acted as financial advisor to BTG olc
  • October 2009
    has been acquired by
    The undersigned acted as financial advisor to Anaspec Inc.
  • August 2009
    has sold its HySolv™ drug delivery technology to
    The undersigned acted as financial advisor to BTG plc
  • January 2009
    has been acquired by
    The undersigned acted as financial advisor to the shareholders of Labcoat Limited
  • December 2008
    has acquired
    The undersigned is acting as financial advisor to Biocompatibles International
  • December 2008
    has acquired
    The undersigned rendered a Fairness Opinion to Affymetrix, Inc.
  • February 2008
    has been acquired by
    The undersigned is acting as financial advisor to Sigma Pharmaceuticals
  • January 2008
    has been acquired by
    The undersigned is acting as financial advisor to Panbio Limited
  • May 2007
    has acquired
    The undersigned acted as financial advisor to Ansell Limited
  • March 2007
    has sold its Human Health point-of-care diagnostic products business to
    The undersigned acted as financial advisor to Agenix Limited
  • February 2007
    Strategic alliance and investment of up to £32,100,000 in
    The undersigned acted as financial advisor to GeneMedix, PLC
  • December 2006
    Announced M&A advisory and restructuring
    The undersigned acted as financial advisor to Panbio Limited
  • December 2006
    has acquired
    The undersigned acted financial advisor to Novozymes A/S
  • August 2006
    has acquired
    The undersigned acted as financial advisor to Meditech Research Limited
  • July 2006
    has acquired Delta Biotechnology Ltd from
    The undersigned acted as financial advisor to Novozymes A/S
  • April 2006
    has assigned IP and granted distribution rights for its Animal Health business to
    The undersigned acted as financial advisor to Agenix Limited
  • October 2005
    M&A advisory and valuation analysis
    The undersigned acted as financial advisor to CogState Limited
  • September 2005
    NASDAQ listing of ADRs (American Depositary Receipts)
    The undersigned acted as advisor to Genetic Technologies Limited
  • June 2005
    NASDAQ listing of ADRs (American Depositary Receipts)
    The undersigned acted as advisor to ChemGenex Pharmarceuticals Limited
  • January 2005
    awarded to
    for its investment banking role in the creation of
  • December 2004
    has been acquired by
    The undersigned acted as financial advisor to AGT Biosciences Ltd.